Norethindrone Acetate And Ethinyl Estradiol Tablet
NDC Package 68462-656-29

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

Norethindrone Acetate And Ethinyl Estradiol tablets are contraindicated in women with any of the following conditions:•Undiagnosed abnormal genital bleeding•Known, suspected, or history of breast cancer •Known or suspected estrogen-dependent neoplasia•Active DVT, PE or a history of these conditions•Active arterial thromboembolic disease (for example, stroke and MI), or a history of these conditions•Known anaphylactic reaction or angioedema to norethindrone acetate and ethinyl estradiol tablets•Known liver impairment or disease •Known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders•Known or suspected pregnancy. This formulation utilizes a tablet delivery system. Marketed by Glenmark Pharmaceuticals Inc., Usa, this product is identified by NDC 68462-656 and is authorized under FDA application ANDA203038.

Identification & Billing

NDC Package Code
68462-656-29
Package Description
3 POUCH in 1 CARTON / 1 BLISTER PACK in 1 POUCH / 28 TABLET in 1 BLISTER PACK
Product Code
11-Digit Billing Format
68462065629
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
3 EA
RxNorm Crosswalk
  • RxCUI: 1090992 - norethindrone acetate 1 MG / ethinyl estradiol 5 MCG Oral Tablet
  • RxCUI: 1090992 - ethinyl estradiol 0.005 MG / norethindrone acetate 1 MG Oral Tablet
  • RxCUI: 1090992 - ethinyl estradiol 5 MCG / norethindrone acetate 1 MG Oral Tablet
  • RxCUI: 1251323 - norethindrone acetate 0.5 MG / ethinyl estradiol 2.5 MCG Oral Tablet
  • RxCUI: 1251323 - ethinyl estradiol 0.0025 MG / norethindrone acetate 0.5 MG Oral Tablet

Clinical Specifications

Proprietary Name
Norethindrone Acetate And Ethinyl Estradiol
Non-Proprietary Name
Norethindrone Acetate And Ethinyl Estradiol
Substance Name
Ethinyl Estradiol; Norethindrone Acetate
Dosage Form
Tablet - A solid dosage form containing medicinal substances with or without suitable diluents.
Administration Route
Oral - Administration to or by way of the mouth.
Usage Information
Norethindrone acetate and ethinyl estradiol tablets are contraindicated in women with any of the following conditions:•Undiagnosed abnormal genital bleeding•Known, suspected, or history of breast cancer •Known or suspected estrogen-dependent neoplasia•Active DVT, PE or a history of these conditions•Active arterial thromboembolic disease (for example, stroke and MI), or a history of these conditions•Known anaphylactic reaction or angioedema to norethindrone acetate and ethinyl estradiol tablets•Known liver impairment or disease •Known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders•Known or suspected pregnancy

Regulatory & Marketing

Labeler Name
Glenmark Pharmaceuticals Inc., Usa
Product Type
Human Prescription Drug
FDA Application #
ANDA203038
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
04-02-2015
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (68462-656). Click a package code to view its specific billing and regulatory data.

90 TABLET in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 68462-656-29 identifies a specific commercial package of 3 pouch in 1 carton / 1 blister pack in 1 pouch / 28 tablet in 1 blister pack of Norethindrone Acetate And Ethinyl Estradiol, a human prescription drug labeled by Glenmark Pharmaceuticals Inc., Usa. This tablet is formulated for oral use and contains ethinyl estradiol; norethindrone acetate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Glenmark Pharmaceuticals Inc., Usa on April 02, 2015. The current certification is valid through December 31, 2027.

How is this Glenmark Pharmaceuticals Inc., Usa product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 68462065629. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 3 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
68462-656-29
11-Digit CMS (5-4-2)
68462-0656-29

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.